|
|
Post by MnkdWASmyRtrmntPlan on Apr 17, 2019 15:28:43 GMT -5
So, this is Torrey Pines and Mannkind, but an inventor is Andrea. Is that because it was started years ago when she still worked at Mannkind, or is it cannabinol-based, or both?
|
|
|
|
Post by figglebird on Apr 17, 2019 15:42:20 GMT -5
from patent...
"Example 5
In a conditioned place preference (CPP) study to evaluate the "reward" or "aversive" value of the drug, mice are conditioned to associate one compartment of the apparatus with treatment. The apparatus itself is "balanced," meaning that mice show no initial preference for one chamber over another (FIG. 5, left-most bar). Reinforcing agents result in an increased place preference for the drug-paired compartment, whereas aversive agents result in a decreased place preference. The experiments were conducted similarly as described in the previous examples. Mice were insufflated with 0.125 mg of morphine or powder formulations containing 0.125 mg of tetrapeptide (D)Phe-(D)Phe-(D)Ile-(D)Arg-NH.sub.2 (SEQ ID NO: 1, Compound 1) or (D)Phe-(D)Phe-(D)Nle-(D)Arg-NH.sub.2 (SEQ ID NO: 2, Compound 2). To test placebo effect, additional mice were insufflated with FDKP (TECHNOSPHERE.RTM.) powder (0.5 mg) without any peptide. The results of these experiments are shown in FIG. 5. The data show that mice insufflated with the placebo powder or the powder containing the tetrapeptide (D)Phe-(D)Phe-(D)Ile-(D)Arg-NH.sub.2 (SEQ ID NO: 1, Compound 1) or (D)Phe-(D)Phe-(D)Nle-(D)Arg-NH.sub.2 (SEQ ID NO: 2, Compound 2) showed no preference for the paired compartment. In contrast, mice treated with morphine exhibited a strong preference for the associated compartment, confirming the expected reward effect provided by the drug.
Accordingly, dry powder formulations for inhalation comprising peptides can provide opioid-like pain relief with fewer adverse effects than current, commercially available analgesics. The inhalation powder has been administered to mice by pulmonary insufflation. In a nonclinical model of acute pain (the 55.degree. C. warm-water tail withdrawal assay), the dry powder formulations comprising the peptides demonstrated analgesic activity comparable to injected morphine without the typical opioid side effects. Unlike mice treated with morphine, those given the dry powder formulations comprising the peptides surprisingly did not exhibit depressed respiration or alterations in spontaneous locomotor activity. Nor did they exhibit a place-conditioning response, a behavior associated with a "reward" after receiving the FDKP/opioid receptor agonist peptide dry powder formulation."
|
|
|
|
Post by peppy on Apr 17, 2019 18:01:47 GMT -5
|
|
|
|
Post by peppy on Apr 17, 2019 18:07:06 GMT -5
from patent..."Example 5 In a conditioned place preference (CPP) study to evaluate the "reward" or "aversive" value of the drug, mice are conditioned to associate one compartment of the apparatus with treatment. The apparatus itself is "balanced," meaning that mice show no initial preference for one chamber over another (FIG. 5, left-most bar). Reinforcing agents result in an increased place preference for the drug-paired compartment, whereas aversive agents result in a decreased place preference. The experiments were conducted similarly as described in the previous examples. Mice were insufflated with 0.125 mg of morphine or powder formulations containing 0.125 mg of tetrapeptide (D)Phe-(D)Phe-(D)Ile-(D)Arg-NH.sub.2 (SEQ ID NO: 1, Compound 1) or (D)Phe-(D)Phe-(D)Nle-(D)Arg-NH.sub.2 (SEQ ID NO: 2, Compound 2). To test placebo effect, additional mice were insufflated with FDKP (TECHNOSPHERE.RTM.) powder (0.5 mg) without any peptide. The results of these experiments are shown in FIG. 5. The data show that mice insufflated with the placebo powder or the powder containing the tetrapeptide (D)Phe-(D)Phe-(D)Ile-(D)Arg-NH.sub.2 (SEQ ID NO: 1, Compound 1) or (D)Phe-(D)Phe-(D)Nle-(D)Arg-NH.sub.2 (SEQ ID NO: 2, Compound 2) showed no preference for the paired compartment. In contrast, mice treated with morphine exhibited a strong preference for the associated compartment, confirming the expected reward effect provided by the drug. Accordingly, dry powder formulations for inhalation comprising peptides can provide opioid-like pain relief with fewer adverse effects than current, commercially available analgesics. The inhalation powder has been administered to mice by pulmonary insufflation. In a nonclinical model of acute pain (the 55.degree. C. warm-water tail withdrawal assay), the dry powder formulations comprising the peptides demonstrated analgesic activity comparable to injected morphine without the typical opioid side effects. Unlike mice treated with morphine, those given the dry powder formulations comprising the peptides surprisingly did not exhibit depressed respiration or alterations in spontaneous locomotor activity. Nor did they exhibit a place-conditioning response, a behavior associated with a "reward" after receiving the FDKP/opioid receptor agonist peptide dry powder formulation." I remember Mike saying a 4th undisclosed Consumer Driven molecule. An analgesic comparable to injected morphine. fits the bill. |
|
|
|
Post by peppy on Apr 17, 2019 18:15:51 GMT -5
Great finding, lets not get too excited. As in past, we get all worked up and nothing comes about. Just like the shipment to Dubai. I had nearly forgotten about the boat to Dubai. You have to give those trying to do upside stock manipulation credit for creativeness. The shorts never come up with truly interesting/funny things like that. mytakeonit still waiting for the ship to sail by the island. Slow Boat. |
|
|
|
Post by mytakeonit on Apr 17, 2019 19:14:18 GMT -5
Boat? So are you going on a cruise ... or is it a pirate ship? Ha! If you're still in that cage ... it could still be either. Too much of a party animal so you got caged ... or caged because the pirates caught you.  But, that's mytakeonit |
|
|
|
Post by mango on Apr 17, 2019 20:14:28 GMT -5
Bucket 4 is the Torrey Pines/MannKind tetrapeptide NCE pain molecule |
|
|
|
Post by peppy on Apr 17, 2019 20:15:58 GMT -5
mango Ah, thank you. I knew I needed you. BTW what is NCE?
|
|
|
|
Post by mango on Apr 17, 2019 20:17:06 GMT -5
Ah, thank you. I knew I needed you. BTW what is NCE? New Chemical Entity Maybe new biologic is the more correct term? |
|
|
|
Post by peppy on Apr 17, 2019 20:19:50 GMT -5
Ah, thank you. I knew I needed you. BTW what is NCE? New Chemical Entity Maybe new biologic is the more correct term? and then I looked. right in front of my face.  Accordingly, dry powder formulations for inhalation comprising peptides can provide opioid-like pain relief with fewer adverse effects than current, commercially available analgesics. The inhalation powder has been administered to mice by pulmonary insufflation. In a nonclinical model of acute pain (the 55.degree. C. warm-water tail withdrawal assay), the dry powder formulations comprising the peptides demonstrated analgesic activity comparable to injected morphine without the typical opioid side effects. Unlike mice treated with morphine, those given the dry powder formulations comprising the peptides surprisingly did not exhibit depressed respiration or alterations in spontaneous locomotor activity. Nor did they exhibit a place-conditioning response, a behavior associated with a "reward" after receiving the FDKP/opioid receptor agonist peptide dry powder formulation."
Wild and crazy thought. Being that the Opioid Crisis is a recognized National Emergency, Wouldn't it be something if an analgesic would be fast tracked to combat the crisis? Does Mannkind have that kind of luck? |
|
|
|
Post by mango on Apr 17, 2019 21:05:24 GMT -5
New Chemical Entity Maybe new biologic is the more correct term? and then I looked. right in front of my face. Accordingly, dry powder formulations for inhalation comprising peptides can provide opioid-like pain relief with fewer adverse effects than current, commercially available analgesics. The inhalation powder has been administered to mice by pulmonary insufflation. In a nonclinical model of acute pain (the 55.degree. C. warm-water tail withdrawal assay), the dry powder formulations comprising the peptides demonstrated analgesic activity comparable to injected morphine without the typical opioid side effects. Unlike mice treated with morphine, those given the dry powder formulations comprising the peptides surprisingly did not exhibit depressed respiration or alterations in spontaneous locomotor activity. Nor did they exhibit a place-conditioning response, a behavior associated with a "reward" after receiving the FDKP/opioid receptor agonist peptide dry powder formulation."
Wild and crazy thought. Being that the Opioid Crisis is a recognized National Emergency, Wouldn't it be something if an analgesic would be fast tracked to combat the crisis? Does Mannkind have that kind of luck? Don't jinx us 🤔🤫🤗😯😶 |
|
|
|
Post by peppy on Apr 17, 2019 21:13:03 GMT -5
brentie, or all, Do you have a copy or a paraphrase of the collaboration agreement between Torry Pines and Mannkind?
|
|
|
|
Post by goyocafe on Aug 27, 2019 5:18:14 GMT -5
J&J might want to take some of the $BB they just saved in the lawsuit and come up with a plan to make it all go away.
|
|
|
|
Post by mnholdem on Aug 27, 2019 5:55:18 GMT -5
J&J hit with over $500MM damages by judge for its role in opioid epidemic. This would be an opportune time for MsnnKind to issue PR that communicated it’s pre-clinical development of non-addicting pain meds and promote their technology even though it’s in the long-term pipeline bucket.
Based upon medical media coverage during the past few years, however, MannKind doesn’t appear to have developed its network of media contacts. Zero coverage of EpiHale during last year’s epinephrine shortage and Mylan woes is just one example of a lost opportunity to promote the pipeline.
During that time period, the dominant discussion on PB was the management’s “team-building” event in Hawaii.
|
|
|
|
Post by goyocafe on Aug 27, 2019 6:12:00 GMT -5
J&J hit with over $500MM damages by judge for its role in opioid epidemic. This would be an opportune time for MsnnKind to issue PR that communicated it’s pre-clinical development of non-addicting pain meds and promote their technology even though it’s in the long-term pipeline bucket. Based upon medical media coverage during the past few years, however, MannKind doesn’t appear to have developed its network of media contacts. Zero coverage of EpiHale during last year’s epinephrine shortage and Mylan woes is just one example of a lost opportunity to promote the pipeline. During that time period, the dominant discussion on PB was the management’s “team-building” event in Hawaii. Yep. A head scratcher. |
|
